High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer

Global Cancer Statistics, 2002

Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,573 · see citing works

Untitled work

(1997) · PubMed · Cited by 1,541 · see citing works

Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer

Ghosh, A., & Heston, W. D. W. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10661 · Cited by 883 · see citing works

Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.

Chang, S. S., Reuter, V. E., Heston, W. D. W., Bander, N. H., Grauer, L. S., & Gaudin, P. B. (1999) · PubMed · Cited by 807 · see citing works

Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy

Wright, G. L., Mayer Grob, B., Haley, C., Grossman, K., Newhall, K., Petrylak, D., Troyer, J., Konchuba, A., Schellhammer, P. F., & Moriarty, R. (1996) · Urology · doi:10.1016/s0090-4295(96)00184-7 · Cited by 635 · see citing works

Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases

SWEAT, S. D., Pacelli, A., Murphy, G. P., & Bostwick, D. G. (1998) · Urology · doi:10.1016/s0090-4295(98)00278-7 · Cited by 609 · see citing works

Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues

Wright, G. L., Haley, C. L., Beckett, M. L., & Schellhammer, P. F. (1995) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/1078-1439(95)00002-y · Cited by 593 · see citing works

Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays.

Bubendorf, L., Kononen, J., Koivisto, P. A., Schraml, P., Moch, H., Gasser, T. C., Willi, N., Mihatsch, M. J., Sauter, G., & Kallioniemi, O. (1999) · PubMed · Cited by 592 · see citing works

Tissue microarray technology for high-throughput molecular profiling of cancer

Kallioniemi, O. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.7.657 · Cited by 568 · see citing works

Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen.

Israeli, R., Powell, C. T., Fair, W. R., & Heston, W. D. W. (1993) · PubMed · Cited by 530 · see citing works

Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium.

Liu, H., Moy, P., Kim, S., Xia, Y., Rajasekaran, A. K., Navarro, V., Knudsen, B., & Bander, N. H. (1997) · PubMed · Cited by 528 · see citing works

Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer.

Ross, J. S., Sheehan, C. E., Fisher, H. A. �., Kaufman, R. P., Kaur, P., Gray, K., Webb, I. J., Gray, G. S., Mosher, R. E., & Kallakury, B. (2003) · PubMed · Cited by 502 · see citing works

Prostate-specific membrane antigen expression as a predictor of prostate cancer progression

Perner, S., Hofer, M. D., Kim, R., Shah, R. B., Li, H., Mӧller, P., Hautmann, R. E., Gschwend, J. E., Kuefer, R., & Rubin, M. A. (2007) · Human Pathology · doi:10.1016/j.humpath.2006.11.012 · Cited by 455 · see citing works

Constitutive and antibody-induced internalization of prostate-specific membrane antigen.

Liu, H., Rajasekaran, A. K., Moy, P., Xia, Y., Kim, S., Navarro, V., Rahmati, R., & Bander, N. H. (1998) · PubMed · Cited by 446 · see citing works

Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis

Mannweiler, S., Amersdorfer, P., Trajanoski, S., Terrett, J. A., King, D., & Méhes, G. (2008) · Pathology & Oncology Research · doi:10.1007/s12253-008-9104-2 · Cited by 386 · see citing works

Expression of Prostate‐Specific Membrane Antigen in Normal and Malignant Human Tissues

Kinoshita, Y., Kuratsukuri, K., LANDAS, S. K., Imaida, K., Rovito, P. M., Wang, C. Y., & Haas, G. P. (2006) · World Journal of Surgery · doi:10.1007/s00268-005-0544-5 · Cited by 382 · see citing works

5162504 Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients

Horoszewicz, J. S., KAWINSKI, E., & Murphy, G. P. (1993) · Biotechnology Advances · doi:10.1016/0734-9750(93)90273-p · Cited by 380 · see citing works

Detection and characterization of the prostate‐specific membrane antigen (PSMA) in tissue extracts and body fluids

Trover, J. K., Beckett, M. L., & Wright, G. L. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910620511 · Cited by 374 · see citing works

Preclinical Evaluation of Novel Glutamate-Urea-Lysine Analogues That Target Prostate-Specific Membrane Antigen as Molecular Imaging Pharmaceuticals for Prostate Cancer

Hillier, S., Maresca, K. P., Femia, F. J., Marquis, J. C., Foss, C. A., Nguyen, N. H., Zimmerman, C. N., Barrett, J. A., Eckelman, W. C., Pomper, M. G., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1682 · Cited by 318 · see citing works

Phase I Trial of Yttrium-90—Labeled Anti—Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Androgen-Independent Prostate Cancer

Milowsky, M. I., Nanus, D. M., Kostakoğlu, L., Vallabhajosula, S., Goldsmith, S. J., & Bander, N. H. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.154 · Cited by 313 · see citing works

Targeting Metastatic Prostate Cancer With Radiolabeled Monoclonal Antibody J591 to the Extracellular Domain of Prostate Specific Membrane Antigen

Bander, N. H., Trabulsi, E. J., Kostakoğlu, L., Yao, D., Vallabhajosula, S., Smith-Jones, P. M., Joyce, M. A., Milowsky, M. I., Nanus, D. M., & Goldsmith, S. J. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000091655.77601.0c · Cited by 263 · see citing works

Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers

Haffner, M. C., Kronberger, I. E., Ross, J. S., Sheehan, C. E., Zitt, M., Mühlmann, G., Öfner, D., Zelger, B. G., Ensinger, C., Yang, X. J., et al. (2009) · Human Pathology · doi:10.1016/j.humpath.2009.06.003 · Cited by 236 · see citing works

Is prostate-specific membrane antigen a multifunctional protein?

Rajasekaran, A. K., Gopalakrishnapillai, A., & Christiansen, J. J. (2005) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00506.2004 · Cited by 233 · see citing works

Randomized Phase II Study of Two Doses of Gefitinib in Hormone-Refractory Prostate Cancer: A Trial of the National Cancer Institute of Canada-Clinical Trials Group

Canil, C. M., Moore, M. J., Winquist, E., Baetz, T. D., Pollak, M., Chi, K. N., Berry, S. R., Ernst, D. S., Douglas, L., Brundage, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.129 · Cited by 209 · see citing works

Clinical significance of p53 alterations in surgically treated prostate cancers

Schlomm, T., Iwers, L., Kirstein, P., Jessen, B., Köllermann, J., Minner, S., Passow-Drolet, A., Mirlacher, M., Milde-Langosch, K., Graefen, M., et al. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.104 · Cited by 196 · see citing works

The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial

Ziada, A. M., Barqawi, A. B., Glode, L. M., Varella‐Garcia, M., Crighton, F., Majeski, S., Rosenblum, M., Kane, M. A., Chen, L., & Crawford, E. D. (2004) · The Prostate · doi:10.1002/pros.20065 · Cited by 181 · see citing works

( 111 ) INDIUM-CAPROMAB PENDETIDE IN THE EVALUATION OF PATIENTS WITH RESIDUAL OR RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMY

Kahn, D. J., Williams, R. D., Manyak, M. J., Haseman, M. K., Seldin, D. W., Libertino, J. A., Maguire, R. T., & The ProstaScint Study Group (1998) · The Journal of Urology · doi:10.1016/s0022-5347(01)63239-7 · Cited by 170 · see citing works

Validating cancer drug targets

Benson, J. D., Chen, Y.-N. P., Cornell-Kennon, S., Dorsch, M., Kim, S., Leszczyniecka, M., Sellers, W. R., & Lengauer, C. (2006) · Nature · doi:10.1038/nature04873 · Cited by 161 · see citing works

A Prostate-Specific Membrane Antigen-Targeted Monoclonal Antibody–Chemotherapeutic Conjugate Designed for the Treatment of Prostate Cancer

Henry, M. D., Wen, S., Silva, M. D., Chandra, S., Milton, M., & Worland, P. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1722 · Cited by 156 · see citing works

Subdiaphragmatic and intrathoracic paraspinal malignant peripheral nerve sheath tumors

Kourea, H. P., Bilsky, M. H., Leung, D. H. Y., Lewis, J. J., & Woodruff, J. M. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980601)82:11 · Cited by 149 · see citing works

Phase I Trial of the Prostate-Specific Membrane Antigen–Directed Immunoconjugate MLN2704 in Patients With Progressive Metastatic Castration-Resistant Prostate Cancer

Galsky, M. D., Eisenberger, M., Moore-Cooper, S., Kelly, W. K., Slovin, S. F., DeLaCruz, A., Lee, Y., Webb, I. J., & Scher, H. I. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0532 · Cited by 145 · see citing works

Low Level Her2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate Cancer

Minner, S. J. P., Jessen, B., Stiedenroth, L., Burandt, E., Köllermann, J. W., Mirlacher, M., Erbersdobler, A., Eichelberg, C., Fisch, M., Brümmendorf, T. H., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2546 · Cited by 144 · see citing works

Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate.

Ross, S., Spencer, S. D., Holcomb, I. N., Tan, C., Hongo, J.-A., Devaux, B., Rangell, L. K., Keller, G. A., Schow, P. W., Steeves, R. M., et al. (2002) · PubMed · Cited by 144 · see citing works

HER‐2 profiling and targeting in prostate carcinoma

Morris, M. J., Reuter, V. E., Kelly, W. K., Slovin, S. F., Kenneson, K., Verbel, D., Osman, I., & Scher, H. I. (2002) · Cancer · doi:10.1002/cncr.10339 · Cited by 138 · see citing works

A low molecular weight PSMA-based fluorescent imaging agent for cancer

Chen, Y., Dhara, S., Banerjee, S. R., Byun, Y., Pullambhatla, M., Mease, R. C., & Pomper, M. G. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.10.017 · Cited by 135 · see citing works

Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia.

Marchal, C., Redondo, M., Padilla, M., Caballero, J., Rodrigo, I., Garcia, J., Quian, J., & Boswick, D. G. (2004) · PubMed · doi:10.14670/hh-19.715 · Cited by 129 · see citing works

Trastuzumab plus docetaxel in HER‐2/neu‐positive prostate carcinoma

Lara, P. N., Chee, K. G., Longmate, J., Ruel, C., Meyers, F. J., Gray, C. R., Edwards, R. G., Gumerlock, P. H., Twardowski, P. W., Doroshow, J. H., et al. (2004) · Cancer · doi:10.1002/cncr.20228 · Cited by 114 · see citing works

Tumour Grade, Proliferation, Apoptosis, Microvessel Density, p53, and bcl-2 in Prostate Cancers: Differences Between Tumours Located in the Transition Zone and in the Peripheral Zone

Erbersdobler, A., Fritz, H., Schnöger, S., Graefen, M., Hammerer, P. G., Huland, H., & Henke, R. P. (2002) · European Urology · doi:10.1016/s0302-2838(01)00021-5 · Cited by 105 · see citing works

A Randomized Phase II Trial of the Antiangiogenic Agent SU5416 in Hormone-Refractory Prostate Cancer

Stadler, W. M., Cao, D., Vogelzang, N. J., Ryan, C. W., Hoving, K., Wright, R., Karrison, T. G., & Vokes, E. E. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0404 · Cited by 86 · see citing works

Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer

Wolf, P., Freudenberg, N., Bühler, P., Alt, K., Schultze‐Seemann, W., Wetterauer, U., & Elsässer‐Beile, U. (2009) · The Prostate · doi:10.1002/pros.21090 · Cited by 81 · see citing works

Biorecognition and Subcellular Trafficking of HPMA Copolymer−Anti-PSMA Antibody Conjugates by Prostate Cancer Cells

Liu, J., Kopečková, P., Bühler, P., Wolf, P., Pan, H., Bauer, H., Elsässer‐Beile, U., & Kopec̆ek, J. (2009) · Molecular Pharmaceutics · doi:10.1021/mp8002682 · Cited by 77 · see citing works

A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer

Elsässer‐Beile, U., Wolf, P., Gierschner, D., Bühler, P., Schultze‐Seemann, W., & Wetterauer, U. (2006) · The Prostate · doi:10.1002/pros.20367 · Cited by 73 · see citing works

An Open-Label, Single-Arm Phase Two Trial of Gefitinib in Patients With Advanced or Metastatic Castration-Resistant Prostate Cancer

Pezaro, C. J., Rosenthal, M. A., Gurney, H., Davis, I. D., Underhill, C. R., Boyer, M. J., Kotasek, D., Solomon, B., & Toner, G. C. (2009) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31818b946b · Cited by 51 · see citing works

The apoptosis linked gene ALG‐2 is dysregulated in tumors of various origin and contributes to cancer cell viability

la Cour, J. M., Høj, B. R., Mollerup, J., Simon, R., Sauter, G., & Berchtold, M. W. (2007) · Molecular Oncology · doi:10.1016/j.molonc.2007.08.002 · Cited by 45 · see citing works

Tissue Microarrays

Dancau, A., Simon, R., Mirlacher, M., & Sauter, G. (2009) · Methods in molecular biology · doi:10.1007/978-1-59745-545-9_4 · Cited by 38 · see citing works

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Sartor, O., de Bono, J., Chi, K. N., Fizazi, K., Herrmann, K., Rahbar, K., Tagawa, S. T., Nordquist, L. T., Vaishampayan, N., El-Haddad, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107322 · Cited by 2,864 · see citing works

The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer

Afshar‐Oromieh, A., Avtzi, E., Giesel, F. L., Holland‐Letz, T., Linhart, H., Eder, M., Eisenhut, M., Boxler, S., Hadaschik, B. A., Kratochwil, C., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2949-6 · Cited by 964 · see citing works

Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients

Afshar‐Oromieh, A., Holland‐Letz, T., Giesel, F. L., Kratochwil, C., Mier, W., Haufe, S., Debus, N., Eder, M., Eisenhut, M., Schäfer, M. K.-H., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3711-7 · Cited by 509 · see citing works

Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer

Paschalis, A., Sheehan, B., Riisnaes, R., Rodrigues, D. N., Gurel, B., Bertan, C., Ferreira, A., Lambros, M. B. K., Seed, G., Yuan, W., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.06.030 · Cited by 455 · see citing works

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

van den Eertwegh, A. J. M., Versluis, J., van den Berg, H. P., Santegoets, S. J. A. M., van Moorselaar, R. J. A., van der Sluis, T. M., Gall, H. E., Harding, T. C., Jooss, K. U., Lowy, I., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70007-4 · Cited by 355 · see citing works

Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT

Schwenck, J., Rempp, H., Reischl, G., Kruck, S., Stenzl, A., Nikolaou, K., Pfannenberg, C., & la Fougère, C. J. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3490-6 · Cited by 269 · see citing works

ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy

Minner, S. J. P., Enodien, M., Sirma, H., Luebke, A. M., Krohn, A., Mayer, P.-S., Simon, R., Tennstedt, P., Müller, J., Scholz, L., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1251 · Cited by 250 · see citing works

SERCA control of cell death and survival

Chemaly, E. R., Troncone, L., & Lebeche, D. (2017) · Cell Calcium · doi:10.1016/j.ceca.2017.07.001 · Cited by 233 · see citing works

PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status

Lütje, S., Heskamp, S., Cornelissen, A. S., Poeppel, T. D., van den Broek, S. A. M. W., Rosenbaum-Krumme, S. J., Bockisch, A., Gotthardt, M., Rijpkema, M., & Boerman, O. C. (2015) · Theranostics · doi:10.7150/thno.13348 · Cited by 224 · see citing works

Engineering a Prostate-Specific Membrane Antigen–Activated Tumor Endothelial Cell Prodrug for Cancer Therapy

Denmeade, S. R., Mhaka, A. M., Rosen, D. M., Brennen, W. N., Dalrymple, S. L., Dach, I., Olesen, C., Gürel, B., Marzo, A. M. D., Wilding, G., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003886 · Cited by 222 · see citing works

177Lu-PSMA Radioligand Therapy for Prostate Cancer

Fendler, W. P., Rahbar, K., Herrmann, K., Kratochwil, C., & Eiber, M. J. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.191023 · Cited by 206 · see citing works

ExoAPP: Exosome-Oriented, Aptamer Nanoprobe-Enabled Surface Proteins Profiling and Detection

Jin, D., Yang, F., Zhang, Y., Liu, L., Zhou, Y., Wang, F., & Zhang, G. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.8b03959 · Cited by 198 · see citing works

Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis

Hupe, M. C., Philippi, C., Roth, D., Kümpers, C., Ribbat-Idel, J., Becker, F., Joerg, V., Duensing, S., Lubczyk, V. H., Kirfel, J., et al. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00623 · Cited by 175 · see citing works

[68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer

Hennrich, U., & Eder, M. (2021) · Pharmaceuticals · doi:10.3390/ph14080713 · Cited by 176 · see citing works

Antibody-Targeted Nanoparticles for Cancer Therapy

Fay, F., & Scott, C. J. (2011) · Immunotherapy · doi:10.2217/imt.11.5 · Cited by 160 · see citing works

Initial Experience with Volumetric 68Ga-PSMA I&T PET/CT for Assessment of Whole-Body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Prostate Cancer

Schmuck, S., von Klot, C. A., Henkenberens, C., Sohns, J. M. S., Christiansen, H., Wester, H., Roß, T. L., Bengel, F. M., & Derlin, T. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.193581 · Cited by 159 · see citing works

Antibody–Drug Conjugate (ADC) Clinical Pipeline: A Review

Sassoon, I., & Blanc, V. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-541-5_1 · Cited by 157 · see citing works

BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence

ICGC Project on Early Onset Prostate Cancer, Gu, L., Frommel, S. C., Oakes, C. C., Simon, R., Grupp, K., Gerig, C. Y., Bär, D., Robinson, M. D., Baer, C. R., et al. (2014) · Nature Genetics · doi:10.1038/ng.3165 · Cited by 150 · see citing works

Serum Glutamate Levels Correlate with Gleason Score and Glutamate Blockade Decreases Proliferation, Migration, and Invasion and Induces Apoptosis in Prostate Cancer Cells

Koochekpour, S., Majumdar, S., Azabdaftari, G., Attwood, K. M., Scioneaux, R., Subramani, D., Manhardt, C. T., Lorusso, G. D., Willard, S. S., Thompson, H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1308 · Cited by 148 · see citing works

PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy

Jones, W. E., Griffiths, K., Barata, P. C., & Paller, C. J. (2020) · Cancers · doi:10.3390/cancers12061367 · Cited by 148 · see citing works

First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer

Zang, J., Fan, X., Wang, H., Liu, Q., Wang, J., Li, H. Y., Li, F., Jacobson, O., Niu, G., Zhu, Z., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4096-y · Cited by 132 · see citing works

Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial

Fizazi, K., Herrmann, K., Krause, B. J., Rahbar, K., Chi, K. N., Morris, M. J., Sartor, O., Tagawa, S. T., Kendi, A. T., Vogelzang, N., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00158-4 · Cited by 125 · see citing works

Prostate-Specific Membrane Antigen Protein Expression in Tumor Tissue and Risk of Lethal Prostate Cancer

Kasperzyk, J. L., Finn, S. P., Flavin, R., Fiorentino, M., Lis, R. L., Hendrickson, W. K., Clinton, S. K., Sesso, H. D., Giovannucci, E. L., Stampfer, M. J., et al. (2013) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-0668 · Cited by 116 · see citing works

Diagnostic accuracy of 68 Ga‐prostate‐specific membrane antigen ( PSMA ) positron‐emission tomography ( PET ) and multiparametric (mp) MRI to detect intermediate‐grade intra‐prostatic prostate cancer using whole‐mount pathology: impact of the addition of 68 Ga‐ PSMA PET to mp MRI

Scheltema, M. J. V., Chang, J. I.-C., Stricker, P. D., van Leeuwen, P. J., Nguyen, Q. A., Ho, B., Delprado, W., Lee, J. W. J., Thompson, J. E., Cusick, T., et al. (2019) · British Journal of Urology · doi:10.1111/bju.14794 · Cited by 113 · see citing works

In Vitro and In Vivo Responses of Advanced Prostate Tumors to PSMA ADC, an Auristatin-Conjugated Antibody to Prostate-Specific Membrane Antigen

Wang, X., Ma, D., Olson, W. C., & Heston, W. D. W. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0191 · Cited by 113 · see citing works

Quantitative ⁶⁸ Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following ¹⁷⁷ Lu-PSMA-617 (VISION Trial)

Kuo, P. H., Morris, M. J., Hesterman, J., Kendi, A. T., Rahbar, K., Wei, X. X., Fang, B., Adra, N., Garje, R., Michalski, J. M., et al. (2024) · Radiology · doi:10.1148/radiol.233460 · Cited by 119 · see citing works

68Ga-PSMA-11 PET/CT in Newly Diagnosed Carcinoma of the Prostate: Correlation of Intraprostatic PSMA Uptake with Several Clinical Parameters

Koerber, S. A., Utzinger, M. T., Kratochwil, C., Kesch, C. V., Haefner, M. F., Katayama, S., Mier, W., Iagaru, A. H., Herfarth, K. K., Haberkorn, U., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.190314 · Cited by 109 · see citing works

External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies

Kurth, J., Krause, B. J., Schwarzenböck, S. M., Stegger, L., Schäfers, M. A., & Rahbar, K. (2018) · EJNMMI Research · doi:10.1186/s13550-018-0386-4 · Cited by 109 · see citing works

Heterogeneous PSMA expression on circulating tumor cells - a potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancer

Gorges, T. M., Riethdorf, S., von Ahsen, O., Nastały, P., Roeck, K., Boede, M. O., Peine, S., Kuske, A., Schmid, E., Kneip, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9004 · Cited by 104 · see citing works

The salivary glands as a dose limiting organ of PSMA- targeted radionuclide therapy: A review of the lessons learnt so far

Heynickx, N., Herrmann, K., Vermeulen, K., Baatout, S., & Aerts, A. (2021) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2021.04.003 · Cited by 100 · see citing works

177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study)

Khreish, F., Ghazal, Z., Marlowe, R. J., Rosar, F., Sabet, A., Maus, S., Linxweiler, J., Bartholomä, M. D., & Ezziddin, S. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05525-7 · Cited by 98 · see citing works

Detection and localisation of primary prostate cancer using 68 gallium prostate‐specific membrane antigen positron emission tomography/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology

Kalapara, A. A., Nzenza, T. C., Pan, H. Y. C., Ballok, Z. E., Ramdave, S., O’Sullivan, R., Ryan, A., Cherk, M. H., Hofman, M. S., Konety, B. R., et al. (2019) · British Journal of Urology · doi:10.1111/bju.14858 · Cited by 96 · see citing works

Using PSMA imaging for prognostication in localized and advanced prostate cancer

Roberts, M. J., Maurer, T., Perera, M., Eiber, M. J., Hope, T. A., Ost, P., Siva, S., Hofman, M. S., Murphy, D. G., Emmett, L., et al. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00670-6 · Cited by 93 · see citing works

Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with 68Ga-PSMA-11-PET

Ferraro, D. A., Rüschoff, J. H., Muehlematter, U. J., Kranzbühler, B., Müller, J., Messerli, M., Husmann, L., Hermanns, T., Eberli, D., Rupp, N. J., et al. (2020) · Theranostics · doi:10.7150/thno.44584 · Cited by 85 · see citing works

Diagnostic performance of 68Ga-PSMA-11 PET/MRI-guided biopsy in patients with suspected prostate cancer: a prospective single-center study

Ferraro, D. A., Becker, A. S., Kranzbühler, B., Mebert, I., Baltensperger, A., Zeimpekis, K., Grünig, H., Messerli, M., Rupp, N. J., Rueschoff, J. H., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05261-y · Cited by 86 · see citing works

Diagnostic Performance of Prostate-specific Membrane Antigen Positron Emission Tomography–targeted biopsy for Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis

Kawada, T., Yanagisawa, T., Rajwa, P., Motlagh, R. S., Mostafaei, H., Quhal, F., Laukhtina, E., Aydh, A., König, F., Pallauf, M., et al. (2022) · European Urology Oncology · doi:10.1016/j.euo.2022.04.006 · Cited by 87 · see citing works

Phase 1 study of PSMA ADC, an antibody‐drug conjugate targeting prostate‐specific membrane antigen, in chemotherapy‐refractory prostate cancer

Petrylak, D. P., Kantoff, P., Vogelzang, N. J., Mega, A., Fleming, M. T., Stephenson, J. J., Frank, R., Shore, N. D., Dreicer, R., McClay, E. F., et al. (2019) · The Prostate · doi:10.1002/pros.23765 · Cited by 84 · see citing works

The Chemical Scaffold of Theranostic Radiopharmaceuticals: Radionuclide, Bifunctional Chelator, and Pharmacokinetics Modifying Linker

Holik, H. A., Ibrahim, F. M., Elaine, A. A., Putra, B. D., Achmad, A., & Kartamihardja, A. H. S. (2022) · Molecules · doi:10.3390/molecules27103062 · Cited by 80 · see citing works

Detection Efficacy of Hybrid 68 Ga-PSMA Ligand PET/CT in Prostate Cancer Patients with Biochemical Recurrence After Primary Radiation Therapy Defined by Phoenix Criteria

Einspieler, I., Rauscher, I., Düwel, C., Kroenke, M., Rischpler, C., Habl, G., Dewes, S., Ott, A., Wester, H., Schwaiger, M., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.184457 · Cited by 79 · see citing works

68Ga-PSMA-617 PET/CT: a promising new technique for predicting risk stratification and metastatic risk of prostate cancer patients

Liu, C., Liu, T., Zhang, N., Liu, Y., Li, N., Du, P., Yang, Y., Liu, M., Gong, K., Yang, X., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4037-9 · Cited by 79 · see citing works

A Prospective Pilot Study of 89 Zr-J591/Prostate Specific Membrane Antigen Positron Emission Tomography in Men with Localized Prostate Cancer Undergoing Radical Prostatectomy

Osborne, J. R., Green, D. A., Spratt, D. E., Lyashchenko, S. K., Fareedy, S. B., Robinson, B. D., Beattie, B. J., Jain, M., Lewis, J. S., Christos, P. J., et al. (2013) · The Journal of Urology · doi:10.1016/j.juro.2013.10.041 · Cited by 79 · see citing works

Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer

Yadav, M. P., Ballal, S., Tripathi, M., Damle, N. A., Sahoo, R. K., Seth, A., & Bal, C. (2016) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000000606 · Cited by 79 · see citing works

Correlation of PSMA-Targeted 18F-DCFPyL PET/CT Findings With Immunohistochemical and Genomic Data in a Patient With Metastatic Neuroendocrine Prostate Cancer

Tosoian, J. J., Gorin, M. A., Rowe, S. P., Andreas, D., Szabó, Z. R., Pienta, K. J., Pomper, M. G., Lotan, T. L., & Ross, A. E. (2016) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2016.09.002 · Cited by 77 · see citing works

Diagnostic Performance of 68 Gallium Labelled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging for Staging the Prostate Cancer with Intermediate or High Risk Prior to Radical Prostatectomy: A Systematic Review and Meta-analysis

Wu, H. M., Xu, T., Wang, X., Yu, Y., Fan, Z.-Y., Li, D.-X., Luo, L., Yang, X.-C., Jiao, W., & Niu, H. (2019) · The World Journal of Men s Health · doi:10.5534/wjmh.180124 · Cited by 78 · see citing works

Renal and Multiorgan Safety of 177 Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy

Herrmann, K., Rahbar, K., Eiber, M., Sparks, R. B., Baca, N., Krause, B. J., Laßmann, M., Jentzen, W., Tang, J., Chicco, D., et al. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.265448 · Cited by 77 · see citing works

Identifying cancer origin using circulating tumor cells

Lu, S.-H., Tsai, W., Chang, Y., Chou, T., Pang, S., Lin, P., Tsai, C., & Chang, Y. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1141839 · Cited by 74 · see citing works

Performance of [68Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy—a multi-centre evaluation of 2533 patients

Afshar‐Oromieh, A., da Cunha, M. L., Wagner, J., Haberkorn, U., Debus, N., Weber, W., Eiber, M., Holland‐Letz, T., & Rauscher, I. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05189-3 · Cited by 73 · see citing works

Association of legumain expression pattern with prostate cancer invasiveness and aggressiveness

Ohno, Y., Nakashima, J., Izumi, M., Ohori, M., Hashimoto, T., & Tachibana, M. (2012) · World Journal of Urology · doi:10.1007/s00345-012-0977-z · Cited by 71 · see citing works

Influence of Androgen Deprivation Therapy on the Uptake of PSMA-Targeted Agents: Emerging Opportunities and Challenges

Bakht, M. K., Oh, S. W., Youn, H., Cheon, G. J., Kwak, C. H., & Kang, K. W. (2016) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-016-0439-4 · Cited by 70 · see citing works

A Multicenter Prospective Clinical Trial of 68Gallium PSMA HBED-CC PET-CT Restaging in Biochemically Relapsed Prostate Carcinoma: Oligometastatic Rate and Distribution Compared With Standard Imaging

McCarthy, M., Francis, R. J., Tang, C., Watts, J., & Campbell, A. M. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.03.014 · Cited by 69 · see citing works

68Ga-PSMA PET/CT Imaging Predicting Intraprostatic Tumor Extent, Extracapsular Extension and Seminal Vesicle Invasion Prior to Radical Prostatectomy in Patients with Prostate Cancer

von Klot, C. A. J., Merseburger, A. S., Böker, A., Schmuck, S., Roß, T. L., Bengel, F. M., Kuczyk, M. A., Henkenberens, C., Christiansen, H., Wester, H., et al. (2017) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-017-0476-7 · Cited by 66 · see citing works

[177Lu]Lu-PSMA-617 Salivary Gland Uptake Characterized by Quantitative In Vitro Autoradiography

Tönnesmann, R., Meyer, P. T., Eder, M., & Baranski, A.-C. (2019) · Pharmaceuticals · doi:10.3390/ph12010018 · Cited by 63 · see citing works

Polymer Nanoparticles and Nanomotors Modified by DNA/RNA Aptamers and Antibodies in Targeted Therapy of Cancer

Šubjaková, V., Oravczová, V., & Hianik, T. (2021) · Polymers · doi:10.3390/polym13030341 · Cited by 62 · see citing works

MALDI mass spectrometric imaging based identification of clinically relevant signals in prostate cancer using large‐scale tissue microarrays

Steurer, S. A., Borkowski, C., Odinga, S., Buchholz, M., Koop, C., Huland, H., Becker, M. S., Witt, M., Trede, D., Omidi, M., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28080 · Cited by 61 · see citing works

The Use of a New CellCollector to Isolate Circulating Tumor Cells from the Blood of Patients with Different Stages of Prostate Cancer and Clinical Outcomes - A Proof-of-Concept Study

Theil, G., Fischer, K., Weber, E., Medek, R., Hoda, R., Lücke, K., & Fornara, P. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158354 · Cited by 61 · see citing works

PSMA, EpCAM, VEGF and GRPR as Imaging Targets in Locally Recurrent Prostate Cancer after Radiotherapy

Rybalov, M., Ananias, H. J. K., Hoving, H. D., van der Poel, H. G., Rosati, S., & de Jong, I. J. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15046046 · Cited by 58 · see citing works

Theranostics with photodynamic therapy for personalized medicine: to see and to treat

Wang, Y., Staudinger, J. N., Mindt, T. L., & Gasser, G. (2023) · Theranostics · doi:10.7150/thno.87363 · Cited by 57 · see citing works

Real-time, Near-Infrared Fluorescence Imaging with an Optimized Dye/Light Source/Camera Combination for Surgical Guidance of Prostate Cancer

Neuman, B. P., Eifler, J. B., Castanares, M. A., Chowdhury, W. H., Chen, Y., Mease, R. C., Ma, R., Mukherjee, A., Lupold, S. E., Pomper, M. G., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0891 · Cited by 57 · see citing works

213 Bi-Labeled Prostate-Specific Membrane Antigen-Targeting Agents Induce DNA Double-Strand Breaks in Prostate Cancer Xenografts

Nonnekens, J., Chatalic, K. L. S., Molkenboer‐Kuenen, J. D. M., Beerens, C. E. M. T., Bruchertseifer, F., Morgenstern, A., Veldhoven-Zweistra, J., Schottelius, M., Wester, H., van Gent, D. C., et al. (2017) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2016.2155 · Cited by 57 · see citing works

The Utility of PET/CT in the Planning of External Radiation Therapy for Prostate Cancer

Calais, J., Cao, M., & Nickols, N. G. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.196444 · Cited by 56 · see citing works

Molecular Profiling of Pooled Circulating Tumor Cells from Prostate Cancer Patients Using a Dual-Antibody-Functionalized Microfluidic Device

Yin, C., Wang, Y., Ji, J., Cai, B., Chen, H., Yang, Z., Wang, K., Luo, C., Zhang, W.-W., Yuan, C., et al. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.7b03536 · Cited by 56 · see citing works

High levels of class III β-tubulin expression are associated with aggressive tumor features in breast cancer

Lebok, P., ÖZTÜRK, M., Heilenkötter, U., Jaenicke, F., Müller, V., Paluchowski, P., Geist, S., Wilke, C., BURANDT, E., Lebeau, A., et al. (2016) · Oncology Letters · doi:10.3892/ol.2016.4206 · Cited by 55 · see citing works

Overexpression of thymidylate synthase (TYMS) is associated with aggressive tumor features and early PSA recurrence in prostate cancer

Burdelski, C. M., Strauss, C., Tsourlakis, M. C., Kluth, M., Hube‐Magg, C., Melling, N., Lebok, P., Minner, S. J. P., Koop, C., Graefen, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3107 · Cited by 54 · see citing works

High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers

Grupp, K., Sanader, S., Sirma, H., Simon, R., Koop, C., Prien, K., Hube‐Magg, C., Salomon, G., Graefen, M., Hans Heinzer, A., et al. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.07.009 · Cited by 54 · see citing works

βIII-Tubulin Overexpression Is an Independent Predictor of Prostate Cancer Progression Tightly Linked to ERG Fusion Status and PTEN Deletion

Tsourlakis, M., Weigand, P., Grupp, K., Kluth, M., Steurer, S. A., Schlomm, T., Graefen, M., Huland, H., Salomon, G., Steuber, T. P., et al. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.11.007 · Cited by 54 · see citing works

PSMA Expression is Highly Homogenous in Primary Prostate Cancer

Tsourlakis, M., Klein, F., Kluth, M., Quaas, A., Graefen, M., Haese, A., Simon, R., Sauter, G., Schlomm, T., & Minner, S. J. P. (2015) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000110 · Cited by 53 · see citing works

Diagnostic performance of 68Gallium-PSMA-11 PET/CT to detect significant prostate cancer and comparison with 18FEC PET/CT

Hoffmann, M. A., Miederer, M., Wieler, H. J., Ruf, C. G., Jakobs, F. M., & Schreckenberger, M. (2017) · Oncotarget · doi:10.18632/oncotarget.22441 · Cited by 51 · see citing works

Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancer

Gannon, P. O., Lessard, L., Stevens, L., Forest, V., Bégin, L. R., Minner, S. J. P., Tennstedt, P., Schlomm, T., Mes‐Masson, A., & Fred Saad, C. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.02.026 · Cited by 48 · see citing works

Development and characterization of a theranostic multimodal anti-PSMA targeting agent for imaging, surgical guidance, and targeted photodynamic therapy of PSMA-expressing tumors

Lütje, S., Heskamp, S., Franssen, G. M., Frielink, C., Kip, A., Hekman, M. C. H., Fracasso, G., Colombatti, M., Herrmann, K., Boerman, O. C., et al. (2019) · Theranostics · doi:10.7150/thno.35274 · Cited by 47 · see citing works

Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer

Jacobsen, F., Taskin, B., Melling, N., Sauer, C., Wittmer, C., Hube‐Magg, C., Kluth, M., Simon, R., Pehrke, D., Beyer, B., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3489-9 · Cited by 46 · see citing works

Immunocapture of prostate cancer cells by use of anti-PSMA antibodies in microdevices

Santana, S. M., Liu, H., Bander, N. H., Gleghorn, J. P., & Kirby, B. J. (2011) · Biomedical Microdevices · doi:10.1007/s10544-011-9616-5 · Cited by 46 · see citing works

Landmarks in the evolution of prostate biopsy

Connor, M. J., Gorin, M. A., Eldred‐Evans, D., Bass, E. J., Desai, A., Dudderidge, T. J., Winkler, M. H., & Ahmed, H. U. (2023) · Nature Reviews Urology · doi:10.1038/s41585-022-00684-0 · Cited by 45 · see citing works

Role of FDG PET/CT in Management of Patients with Prostate Cancer

Sutherland, D. E. K., Azad, A., Murphy, D. G., Eapen, R. S., Kostos, L. K., & Hofman, M. S. (2023) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2023.06.005 · Cited by 45 · see citing works

The impact of the number of cores on tissue microarray studies investigating prostate cancer biomarkers

Simon, R. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1216 · Cited by 45 · see citing works

The effect of androgen deprivation therapy on 68Ga-PSMA tracer uptake in non-metastatic prostate cancer patients

Önal, C., Güler, O. C., Torun, N., Reyhan, M., & Yapar, A. F. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04581-4 · Cited by 45 · see citing works

Induction of PSMA and Internalization of an Anti-PSMA mAb in the Vascular Compartment

Nguyen, D. P., Xiong, P. L., Liu, H., Pan, S. M., Leconet, W., Navarro, V., Guo, M., Moy, J., Kim, S., Ramirez‐Fort, M. K., et al. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0193 · Cited by 44 · see citing works

Molecular Imaging in Oncology Using Positron Emission Tomography

Derlin, T., Grünwald, V., Steinbach, J., Wester, H., & Roß, T. L. (2018) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2018.0175 · Cited by 44 · see citing works

Effective Diagnosis of Prostate Cancer Based on mRNAs From Urinary Exosomes

Gan, J., Zeng, X., Wang, X., Wu, Y., Lei, P., Wang, Z., Yang, C., & Hu, Z. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.736110 · Cited by 43 · see citing works

Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrence

Grupp, K., Kohl, S., Sirma, H., Simon, R., Steurer, S. A., Becker, A., Adam, M., Izbicki, J. R., Sauter, G., Minner, S. J. P., et al. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.206 · Cited by 43 · see citing works

p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer

Lebok, P., Roming, M., Kluth, M., Koop, C., Özden, C., Taskin, B., Hussein, K., Lebeau, A., Witzel, I., Woelber, L. L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13227 · Cited by 43 · see citing works

Meeting report from the Prostate Cancer Foundation PSMA‐directed radionuclide scientific working group

Miyahira, A. K., Pienta, K. J., Morris, M. J., Bander, N. H., Baum, R. P., Fendler, W. P., Goeckeler, W. F., Gorin, M. A., Hennekes, H., Pomper, M. G., et al. (2018) · The Prostate · doi:10.1002/pros.23642 · Cited by 43 · see citing works

68Ga-PSMA-11 PET/CT in restaging castration-resistant nonmetastatic prostate cancer: detection rate, impact on patients’ disease management and adequacy of impact

Fourquet, A., Aveline, C., Cussenot, O., Créhange, G., Montravers, F., Talbot, J., & Gauthé, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-58975-8 · Cited by 43 · see citing works

Integrated 68Gallium Labelled Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Magnetic Resonance Imaging Enhances Discriminatory Power of Multi-Parametric Prostate Magnetic Resonance Imaging

Al-Bayati, M., Grueneisen, J. S., Lütje, S., Sawicki, L. M., Suntharalingam, S., Tschirdewahn, S., Forsting, M., Rubben, H., Herrmann, K., Umutlu, L., et al. (2018) · Urologia Internationalis · doi:10.1159/000484695 · Cited by 41 · see citing works

Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues

Bonk, S., Kluth, M., Hube‐Magg, C., Polonski, A., Sökeland, G., Makrypidi‐Fraune, G., Möller‐Koop, C., Witt, M., Luebke, A. M., Hinsch, A., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.27145 · Cited by 41 · see citing works

Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer

Plichta, K. A., Graves, S. A., & Buatti, J. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212095 · Cited by 39 · see citing works

SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence

Grupp, K., Diebel, F., Sirma, H., Simon, R., Breitmeyer, K., Steurer, S. A., Hube‐Magg, C., Prien, K., Pham, T., Weigand, P., et al. (2013) · The Prostate · doi:10.1002/pros.22707 · Cited by 39 · see citing works

Loss of pSer2448‐mTOR expression is linked to adverse prognosis and tumor progression in ERG‐fusion‐positive cancers

Müller, J., Ehlers, A., Burkhardt, L., Sirma, H., Steuber, T. P., Graefen, M., Sauter, G., Minner, S. J. P., Simon, R., Schlomm, T., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27768 · Cited by 39 · see citing works

Prostate-specific membrane antigen targeted protein contrast agents for molecular imaging of prostate cancer by MRI

Pu, F., Salarian, M., Xue, S., Qiao, J., Feng, J., Tan, S., Patel, A., Li, X., Mamouni, K., Hekmatyar, K., et al. (2016) · Nanoscale · doi:10.1039/c5nr09071g · Cited by 39 · see citing works

Comparison of 68Ga-PSMA-617 PET/CT with mpMRI for the detection of PCa in patients with a PSA level of 4–20 ng/ml before the initial biopsy

Li, Y., Han, D., Wu, P., Ren, J., Ma, S., Zhang, J., Song, W., Lin, X., Jiao, D., Shi, S., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-67385-9 · Cited by 39 · see citing works

PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation

Machulkin, A. E., Uspenskaya, A. A., Zyk, N. Y., Nimenko, E. A., Ber, A. P., Petrov, S. A., Shafikov, R. R., Skvortsov, D. A., Smirnova, G. B., Borisova, Y. A., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113936 · Cited by 39 · see citing works

Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer

Chi, K. N., Armstrong, A. J., Krause, B. J., Herrmann, K., Rahbar, K., de Bono, J. S., Adra, N., Garje, R., Michalski, J. M., Kempel, M. M., et al. (2024) · European Urology · doi:10.1016/j.eururo.2023.12.004 · Cited by 37 · see citing works

Comparative analysis of monoclonal antibodies against prostate-specific membrane antigen (PSMA)

Tykvart, J., Navrátil, V., Sedlák, F., Corey, E., Colombatti, M., Fracasso, G., Koukolík, F., Bařinka, C., Šácha, P., & Konvalinka, J. (2014) · The Prostate · doi:10.1002/pros.22887 · Cited by 36 · see citing works

Gallium-68 Prostate-Specific Membrane Antigen PET Imaging

Hofman, M. S., & Iravani, A. (2017) · PET Clinics · doi:10.1016/j.cpet.2016.12.004 · Cited by 35 · see citing works

PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy

Wang, H., Amiel, T., Würnschimmel, C., Langbein, T., Steiger, K., Rauscher, I., Horn, T. D., Maurer, T., Weber, W., Wester, H., et al. (2021) · EJNMMI Research · doi:10.1186/s13550-021-00818-2 · Cited by 35 · see citing works

Evaluation of Phage Display Discovered Peptides as Ligands for Prostate-Specific Membrane Antigen (PSMA)

Shen, D., Xie, F., & Edwards, W. B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068339 · Cited by 35 · see citing works

Integration of 68Ga-PSMA-PET/CT in Radiotherapy Planning for Prostate Cancer Patients

Önal, C., Torun, N., Akyol, F. H., Güler, O. C., Hürmüz, P., Yıldırım, B. A., Çağlar, M., Reyhan, M., & Özyiğit, G. (2019) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002691 · Cited by 34 · see citing works

Targeting the TMPRSS2/ERG fusion mRNA using liposomal nanovectors enhances docetaxel treatment in prostate cancer

Shao, L., Kahraman, N., Ge, Y., Wang, J., Özpolat, B., & Ittmann, M. (2019) · The Prostate · doi:10.1002/pros.23918 · Cited by 34 · see citing works

Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies

Matthias, J., Engelhardt, J., Schäfer, M. K.-H., Bauder‐Wüst, U., Meyer, P. T., Haberkorn, U., Eder, M., Kopka, K., Hell, S. W., & Eder, A.-C. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1624 · Cited by 34 · see citing works

Dual contrast agents for fluorescence and photoacoustic imaging: evaluation in a murine model of prostate cancer

Lesniak, W. G., Wu, Y., Kang, J., Boinapally, S., Banerjee, S. R., Lisok, A., Jabłońska, A., Boctor, E. M., & Pomper, M. G. (2021) · Nanoscale · doi:10.1039/d1nr00669j · Cited by 34 · see citing works

Role of TMPRSS2-ERG Gene Fusion in Negative Regulation of PSMA Expression

Yin, L., Rao, P., Elson, P. J., Wang, J., Ittmann, M., & Heston, W. D. W. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021319 · Cited by 34 · see citing works

Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer.

Ross, J. S., Sheehan, C. E., Fisher, H. A. �., Kaufman, R. P., Kaur, P., Gray, K., Webb, I. J., Gray, G. S., Mosher, R. E., & Kallakury, B. (2003) · PubMed · Cited by 502 · see citing works

Prostate-specific membrane antigen expression as a predictor of prostate cancer progression

Perner, S., Hofer, M. D., Kim, R., Shah, R. B., Li, H., Mӧller, P., Hautmann, R. E., Gschwend, J. E., Kuefer, R., & Rubin, M. A. (2007) · Human Pathology · doi:10.1016/j.humpath.2006.11.012 · Cited by 455 · see citing works

Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues

Wright, G. L., Haley, C. L., Beckett, M. L., & Schellhammer, P. F. (1995) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/1078-1439(95)00002-y · Cited by 593 · see citing works

Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia.

Marchal, C., Redondo, M., Padilla, M., Caballero, J., Rodrigo, I., Garcia, J., Quian, J., & Boswick, D. G. (2004) · PubMed · doi:10.14670/hh-19.715 · Cited by 129 · see citing works

Expression of prostate specific membrane antigen (PSMA) in prostatic \nadenocarcinoma and prostatic intraepithelial neoplasia

Marchal, C., Redondo, M., Padilla, M., Caballero, J., Rodrigo, I., García, J., Quian, J., & Boswick, D. G. (2004) · Digitum: Institutional Repository of the University of Murcia (University of Murcia)